Investors

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes, announces it has received its first order from a leading weight management brand in the United States of America (“USA”).

The order is for SlimBiome® as an ingredient which will be incorporated into a range of flavoured drinks, similar to SlimBiome Medical, which reduces hunger. The products will be included in one of the USA’s leading weight management brands. SlimBiome® has undergone multiple human studies which show its ability to reduce hunger and food cravings which leads to lower calorie intake. OptiBiotix has been working with this brand for over 18 months to carry out human studies which allows the brand to make health claims of hunger control on its products in the USA. Scientifically substantiated health claims help to differentiate these products from others on the market. In the changing landscape of this market, brought about by the anti-obesity drugs, consumers are actively looking for natural, science backed appetite support products. SlimBiome® meets this developing trend.

OptiBiotix expect further orders for a second product, a tablet containing SlimBiome®, within H1 2025. Whilst it is too early to understand the potential scale of the opportunity, this news is material in that it represents the inclusion of SlimBiome® in products of one of the USA’s most popular weight management brands. Further information on the partner and brand will be announced on launch which the Company anticipates will be in H1 2025. However, the Company reminds investors that launch timescales are dictated by the brand owner and these can be subject to change.

Stephen O’Hara, CEO of OptiBiotix Health plc said: “We are pleased to announce the first order for the use of SlimBiome® in one of the USA’s leading weight management brands. The use of SlimBiome® has allowed the brand to make health claims of hunger control on its products which differentiate them from other products on the market. We anticipate more orders and product launches with this brand as it extends the range of products containing SlimBiome® in the USA market in 2025.

“Following the launch of the anti-obesity drugs, natural non-drug alternatives to reduce hunger and cravings are actively being sought by consumers. This announcement demonstrates that the science and multiple human studies carried out on SlimBiome® is now attracting the interest of major brands around the world.”

The Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc	www.optibiotix.com
Neil Davidson, Chairman		Contact via Walbrook below
Stephen O'Hara, Chief Executive
Cairn Financial Advisers LLP (NOMAD)	Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Peterhouse Capital Limited (Broker)	Tel: 020 7220 9797
Duncan Vasey / Lucy Williams
Walbrook PR Ltd
Anna Dunphy	Mob: 07876 741 001

 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.